BRPI1008661A2 - derivados e remédios de aminopirazina - Google Patents
derivados e remédios de aminopirazinaInfo
- Publication number
- BRPI1008661A2 BRPI1008661A2 BRPI1008661A BRPI1008661A BRPI1008661A2 BR PI1008661 A2 BRPI1008661 A2 BR PI1008661A2 BR PI1008661 A BRPI1008661 A BR PI1008661A BR PI1008661 A BRPI1008661 A BR PI1008661A BR PI1008661 A2 BRPI1008661 A2 BR PI1008661A2
- Authority
- BR
- Brazil
- Prior art keywords
- remedies
- aminopyrazine derivatives
- aminopyrazine
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009026470 | 2009-02-06 | ||
| JP2009-026470 | 2009-02-06 | ||
| JP2009276133 | 2009-12-04 | ||
| JP2009-276133 | 2009-12-04 | ||
| PCT/JP2010/051722 WO2010090290A1 (ja) | 2009-02-06 | 2010-02-05 | アミノピラジン誘導体及び医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1008661A2 true BRPI1008661A2 (pt) | 2016-03-08 |
| BRPI1008661B1 BRPI1008661B1 (pt) | 2020-09-15 |
| BRPI1008661B8 BRPI1008661B8 (pt) | 2021-05-25 |
Family
ID=42542181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008661A BRPI1008661B8 (pt) | 2009-02-06 | 2010-02-05 | compostos derivados de aminopirazina, seu uso e composição farmacêutica |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8673891B2 (pt) |
| EP (1) | EP2394999B1 (pt) |
| JP (1) | JP5263304B2 (pt) |
| KR (1) | KR101677778B1 (pt) |
| CN (1) | CN102307869B (pt) |
| AU (1) | AU2010211672B2 (pt) |
| BR (1) | BRPI1008661B8 (pt) |
| CA (1) | CA2751695C (pt) |
| DK (1) | DK2394999T3 (pt) |
| ES (1) | ES2453474T3 (pt) |
| HR (1) | HRP20140265T1 (pt) |
| MX (1) | MX2011008243A (pt) |
| MY (1) | MY155374A (pt) |
| PL (1) | PL2394999T3 (pt) |
| PT (1) | PT2394999E (pt) |
| RU (1) | RU2535217C2 (pt) |
| SI (1) | SI2394999T1 (pt) |
| WO (1) | WO2010090290A1 (pt) |
| ZA (1) | ZA201105623B (pt) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140265T1 (hr) * | 2009-02-06 | 2014-04-25 | Nippon Shinyaku Co., Ltd. | Derivat aminopirazina i odgovarajuä†i lijek |
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| NZ597379A (en) | 2009-06-29 | 2014-04-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| JPWO2012005299A1 (ja) * | 2010-07-07 | 2013-09-05 | 日本新薬株式会社 | Ｒｏｓチロシンキナーゼ阻害剤 |
| WO2012020787A1 (ja) * | 2010-08-11 | 2012-02-16 | 日本新薬株式会社 | 悪性リンパ腫治療剤 |
| JPWO2012020786A1 (ja) * | 2010-08-11 | 2013-10-28 | 日本新薬株式会社 | 医薬組成物 |
| JP5976778B2 (ja) * | 2011-04-11 | 2016-08-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体 |
| SMT201800354T1 (it) | 2011-05-03 | 2018-09-13 | Agios Pharmaceuticals Inc | Attivatori della piruvato chinasi per uso in terapia |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| US9199962B2 (en) | 2011-07-07 | 2015-12-01 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
| EP2554544A1 (en) * | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| TWI547493B (zh) * | 2011-09-27 | 2016-09-01 | 諾華公司 | 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮 |
| EP3984997B1 (en) | 2012-01-06 | 2025-07-30 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9187453B2 (en) | 2012-03-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CA2888360A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| WO2014067962A1 (de) | 2012-10-31 | 2014-05-08 | Bayer Cropscience Ag | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
| WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
| KR20150127197A (ko) * | 2013-03-14 | 2015-11-16 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| WO2014147586A1 (en) * | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
| EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC CONNECTION |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| CN105492435B (zh) | 2013-07-11 | 2018-06-29 | 安吉奥斯医药品有限公司 | 作为idh2突变体抑制剂的化合物 |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015016206A1 (ja) | 2013-07-30 | 2015-02-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2016532721A (ja) | 2013-10-07 | 2016-10-20 | バイエル ファーマ アクチエンゲゼルシャフト | 環状チエノウラシルカルボキサミドおよびその使用 |
| NZ723859A (en) | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| US20170239351A1 (en) | 2014-08-11 | 2017-08-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| JP2017214291A (ja) * | 2014-10-09 | 2017-12-07 | 国立大学法人 宮崎大学 | 骨髄線維化の抑制剤 |
| WO2016200827A1 (en) * | 2015-06-11 | 2016-12-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | P62-zz chemical inhibitor |
| US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| PT3362065T (pt) | 2015-10-15 | 2024-06-21 | Servier Lab | Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda |
| EP3362066B1 (en) | 2015-10-15 | 2021-10-06 | Les Laboratoires Servier SAS | Combination therapy for treating malignancies |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| EP3689862A4 (en) | 2017-09-28 | 2021-01-27 | Nippon Shinyaku Co., Ltd. | CRYSTALS |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
| WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
| WO2021062163A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| WO2021231798A1 (en) | 2020-05-13 | 2021-11-18 | Disc Medicine, Inc. | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2023175932A1 (ja) * | 2022-03-18 | 2023-09-21 | 日本新薬株式会社 | 高リスク骨髄線維症の治療剤 |
| WO2025049402A1 (en) * | 2023-08-28 | 2025-03-06 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| AU5020400A (en) * | 1999-05-20 | 2000-12-12 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| CA2383546A1 (en) * | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| CA2401016A1 (en) * | 2000-02-25 | 2001-08-30 | University Of California | Scytonemin and methods of using thereof |
| AU2003284399A1 (en) * | 2002-11-14 | 2004-06-03 | Kyowa Hakko Kogyo Co., Ltd. | Plk inhibitors |
| WO2005049602A1 (en) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| CN101273039A (zh) | 2005-08-12 | 2008-09-24 | 默克公司 | 可用作p38激酶抑制剂的杂二环化合物 |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| CN102131788B (zh) * | 2008-04-07 | 2014-03-19 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| HRP20140265T1 (hr) * | 2009-02-06 | 2014-04-25 | Nippon Shinyaku Co., Ltd. | Derivat aminopirazina i odgovarajuä†i lijek |
-
2010
- 2010-02-05 HR HRP20140265AT patent/HRP20140265T1/hr unknown
- 2010-02-05 AU AU2010211672A patent/AU2010211672B2/en not_active Ceased
- 2010-02-05 MX MX2011008243A patent/MX2011008243A/es active IP Right Grant
- 2010-02-05 RU RU2011136825/04A patent/RU2535217C2/ru active
- 2010-02-05 EP EP10738621.1A patent/EP2394999B1/en active Active
- 2010-02-05 DK DK10738621.1T patent/DK2394999T3/da active
- 2010-02-05 CA CA2751695A patent/CA2751695C/en active Active
- 2010-02-05 SI SI201030584T patent/SI2394999T1/sl unknown
- 2010-02-05 JP JP2010549525A patent/JP5263304B2/ja not_active Expired - Fee Related
- 2010-02-05 ES ES10738621.1T patent/ES2453474T3/es active Active
- 2010-02-05 US US13/147,001 patent/US8673891B2/en active Active
- 2010-02-05 BR BRPI1008661A patent/BRPI1008661B8/pt not_active IP Right Cessation
- 2010-02-05 CN CN201080007190.XA patent/CN102307869B/zh not_active Expired - Fee Related
- 2010-02-05 PT PT107386211T patent/PT2394999E/pt unknown
- 2010-02-05 KR KR1020117020565A patent/KR101677778B1/ko active Active
- 2010-02-05 MY MYPI2011003643A patent/MY155374A/en unknown
- 2010-02-05 PL PL10738621T patent/PL2394999T3/pl unknown
- 2010-02-05 WO PCT/JP2010/051722 patent/WO2010090290A1/ja not_active Ceased
-
2011
- 2011-07-29 ZA ZA2011/05623A patent/ZA201105623B/en unknown
-
2013
- 2013-01-17 US US13/743,550 patent/US8586591B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR101677778B1 (ko) | 2016-11-18 |
| US20110288065A1 (en) | 2011-11-24 |
| KR20110120932A (ko) | 2011-11-04 |
| DK2394999T3 (da) | 2014-05-05 |
| CA2751695C (en) | 2017-11-28 |
| SI2394999T1 (sl) | 2014-05-30 |
| US20130131082A1 (en) | 2013-05-23 |
| WO2010090290A1 (ja) | 2010-08-12 |
| ZA201105623B (en) | 2012-07-25 |
| JPWO2010090290A1 (ja) | 2012-08-09 |
| MY155374A (en) | 2015-10-15 |
| MX2011008243A (es) | 2011-08-17 |
| US8673891B2 (en) | 2014-03-18 |
| EP2394999A4 (en) | 2012-10-10 |
| EP2394999A1 (en) | 2011-12-14 |
| AU2010211672A1 (en) | 2011-08-25 |
| JP5263304B2 (ja) | 2013-08-14 |
| US8586591B2 (en) | 2013-11-19 |
| BRPI1008661B8 (pt) | 2021-05-25 |
| PL2394999T3 (pl) | 2014-06-30 |
| CA2751695A1 (en) | 2010-08-12 |
| RU2535217C2 (ru) | 2014-12-10 |
| HRP20140265T1 (hr) | 2014-04-25 |
| EP2394999B1 (en) | 2014-01-29 |
| ES2453474T3 (es) | 2014-04-07 |
| CN102307869B (zh) | 2014-10-22 |
| RU2011136825A (ru) | 2013-03-20 |
| CN102307869A (zh) | 2012-01-04 |
| AU2010211672B2 (en) | 2016-08-04 |
| PT2394999E (pt) | 2014-05-02 |
| BRPI1008661B1 (pt) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008661A2 (pt) | derivados e remédios de aminopirazina | |
| BRPI1016117A2 (pt) | derivados de isoxazol-isoxazol e isoxasol-isotiazol. | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
| BRPI0920521A2 (pt) | combinação farmacêutica | |
| BRPI1013642A2 (pt) | derivado de triazina e composição farmacêutica compreendendo o mesmo | |
| BRPI1010881A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| BRPI1010882A2 (pt) | derivados de triazina e suas aplicações terapêuticas. | |
| HRP20160579T1 (hr) | Spoj indola i njegova farmaceutska upotreba | |
| EP2433940A4 (en) | SPIROIMIDAZOLONDERIVAT | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| BR112012010242A2 (pt) | derivados de heteroarilpiperidina e heteroarilpiperazina | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| DK2397480T3 (da) | Diazepindionderivat | |
| BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| DK2387580T3 (da) | Deoxyactagardinderivater | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| BRPI1007196A2 (pt) | profármacos e derivado de espiroindolinona | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| EP2492266A4 (en) | 5-hydroxypyrimidine-4-carboxamide | |
| EP2401281A4 (en) | PYRIMIDINPYRIMIDOINDAZOLDERIVAT | |
| BRPI1011416A2 (pt) | derivados de antraquinova novos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |